Provided by Tiger Fintech (Singapore) Pte. Ltd.

Femasys Inc

1.20
-0.0400-3.23%
Post-market: 1.200.00000.00%17:10 EDT
Volume:85.25K
Turnover:101.96K
Market Cap:32.58M
PE:-1.42
High:1.23
Open:1.19
Low:1.17
Close:1.24
Loading ...

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Feb

Femasys Announces UK Regulatory Approvals for Femaseed® for Female Infertility Treatment and Two Diagnostic Devices

THOMSON REUTERS
·
11 Feb

Femasys announces Israeli regulatory approvals for FemaSeed treatment

TIPRANKS
·
04 Feb

Femasys -Israeli Regulatory Approvals for Femaseed for Female Infertility Treatment and Two Diagnostic Devices

THOMSON REUTERS
·
04 Feb

Femasys announces notices of intention to grant 2 European patent applications

TIPRANKS
·
30 Jan

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of Fembloc Permanent Birth Control

THOMSON REUTERS
·
30 Jan

Femasys Gets Notice of Allowance for New US FemaSeed Patent

MT Newswires Live
·
17 Jan

BRIEF-Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Reuters
·
16 Jan

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of Femaseed® for Female Infertility Treatment

THOMSON REUTERS
·
16 Jan

Femasys Inc: Expects Resulting Patent, When Issued, Will Have an Anticipated Expiration in 2044 at Earliest

THOMSON REUTERS
·
16 Jan

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Femasys announces partnership with HRC Fertility

TIPRANKS
·
03 Dec 2024

Femasys Announces Partnership With Hrc Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer Femaseed

THOMSON REUTERS
·
03 Dec 2024

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Nov 2024

Buy Recommendation for Femasys Driven by Promising FemaSeed Study Results and Market Potential

TIPRANKS
·
27 Nov 2024

Femasys announces peer-reviewed data from FemaSeed ITI in JGRM

TIPRANKS
·
26 Nov 2024

Femasys Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
15 Nov 2024

Femasys’s Strategic Growth: Innovative Product Launches and Expansions in Women’s Health

TIPRANKS
·
14 Nov 2024

Femasys price target lowered to $8 from $10 at Chardan

TIPRANKS
·
13 Nov 2024

Promising Outlook for Femasys Amid Strategic Partnerships and Product Advancements

TIPRANKS
·
13 Nov 2024